市場調查報告書

全球痔瘺治療市場:2020-2026

Global Anal Fistula Therapeutics Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 949663
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
全球痔瘺治療市場:2020-2026 Global Anal Fistula Therapeutics Market 2020-2026
出版日期: 2020年06月27日內容資訊: 英文
簡介

在預測期內,估計全球痔瘺治療市場將顯著增長。 IBD的高流行主要是推動市場增長。新的非手術選擇有望為市場增長提供機會。纖維蛋白膠和alloficell(darvadstrocel)是市場上用於治療痔瘺的非手術選擇。當患者處於全身麻醉狀態時,纖維蛋白膠可以使外科醫生將膠水注入瘺管。這種粘合劑可密封瘺管並幫助其癒合。它通常不如具有簡單瘺管的瘺管切口有效。

結果可能不會持續很長時間。但是,穿過肛門括約肌的瘺管可能是瘺管的替代方法,因為它不需要切割。如果瘺管對至少一種傳統或生物療法的反應較差,Alloficell(darvadstrocel)是患有無效/輕度活動性管腔克羅恩病的成年患者的複合體是第一個治療大肛周瘺管的干細胞療法。預計將來會引入更多非手術選擇,這可能會為市場增長提供重要機會。

在地理上,由於IBD的流行和該地區相當大的健康意識,北美在2019年佔據了最大的市場佔有率。根據疾病控制與預防中心(CDC)的數據,2015年,美國有近1.3%(300萬)成年人被診斷出患有IBD(潰瘍性結腸炎或克羅恩氏病)。炎症或受傷器官是IBD的常見併發症,在克羅恩病中比潰瘍性結腸炎更常見,它更容易形成瘺管。因此,IBD的日益普及為市場增長做出了貢獻。

該報告調查了全球痔瘺治療市場,並提供了按治療,應用,最終用戶和地區劃分的市場概況以及趨勢,以及進入該市場的公司的概況。

內容

第1章報告概述

第2章市場概述和見解

  • 調查範圍
  • 分析師見解和當前市場趨勢
  • 規則和規定

第3章競爭情況

  • 公司佔有率分析
  • 主要策略分析
  • 主要公司分析
    • Medtronic plc
    • Karl Storz SE&Co. KG
    • Cook Group Inc.
    • Takeda Pharmaceutical Co. Ltd.
    • Signum Surgical Ltd.

第4章市場決定因素

  • 動機
  • 抑制因子
  • 市場機會

第5章市場細分

  • 全球肛門瘺治療市場(按治療)
    • 外科
    • 非手術
  • 全球痔瘺治療應用市場
    • 括約肌筋間痔瘺
    • 括約肌筋痔瘺
    • 括約肌痔瘺
    • 其他
  • 最終用戶的全球痔瘺治療市場
    • 醫院
    • 門診手術中心
    • 其他

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第7章公司簡介

  • Medtronic plc
  • Cook Group Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Karl Storz SE & Co. KG
  • Biolitec AG
  • Pfizer Inc.
  • Becton, Dickinson and Co.
  • GEM S.r.l.
  • TiGenix NV
  • W. L. Gore & Associates, Inc.
  • AstraZeneca plc
  • Agency for Medical Innovations (A.M.I.) GmbH
  • Signum Surgical Ltd.
  • Novartis International AG
  • Assembly Biosciences, Inc.
  • Ovesco Endoscopy AG
目錄
Product Code: OMR2021982

Global Anal Fistula Therapeutics Market Size, Share & Trends Analysis Report, By Treatment (Surgical and Non-Surgical), By Application (Intersphincteric Fistula, Transsphincteric Fistula, Suprasphincteric Fistula, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others) and Forecast, 2020-2026

The global anal fistula therapeutics market is estimated to grow significantly during the forecast period. The significant prevalence of IBD is primarily driving the growth of the market. Emerging non-surgical alternatives is expected to offer an opportunity for market growth. Fibrin glue and Alofisel (darvadstrocel) are the non-surgical alternatives available in the market for the treatment of anal fistula. Fibrin glue involves injecting a glue by the surgeon into the fistula when the patient is under general anaesthetic. This glue enables to seal the fistula and supports it to heal. It is usually less effective compared to fistulotomy for simple fistulas.

Its results may not last for a longer period; however, it may be a helpful alternative for fistulas that pass through the anal sphincter muscles as the cut is not required there. Alofisel (darvadstrocel) is the first stem cell therapy to treat complex perianal fistulas in adult patients suffering from nonactive/mildly active luminal Crohn's disease when fistulas have shown an insufficient response to at least one traditional or biologic therapy. More non-surgical alternatives are expected to be introduced in the future, which will likely present a significant opportunity for the growth of the market.

Geographically, in 2019, North America held the largest share in the market owing to the rising prevalence of IBD and considerable health awareness in the region. As per the Centers for Disease Control and Prevention (CDC), in 2015, nearly 1.3% of the US adults (3 million) were reported being diagnosed with IBD (either ulcerative colitis or Crohn's disease). Increased chances of developing fistulas occur when the organ becomes inflamed or injured, which is a common complication of IBD, found most frequently in Crohn's disease than ulcerative colitis. Therefore, the rising prevalence of IBD is contributing to the growth of the market.

Some key players in the market include Medtronic plc, Karl Storz SE & Co. KG, Cook Group Inc., Takeda Pharmaceutical Co. Ltd., and Signum Surgical Ltd. Medtronic offers Permacol collagen paste, which is a minimally invasive treatment for anal fistula. It is made of porcine dermal, acellular collagen suspended in saline. It may be utilized as a single treatment alternative or in combination with other treatment including the ligation of intersphincteric fistula tract (LIFT) technique. Signum Surgical developed the BioHealx device, for improvement in surgical procedures to fulfil all identified essential clinical requirements for reliable healing of heal anal fistulas.

Research Methodology

The market study of the global anal fistula therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Anal Fistula Therapeutics Market Research and Analysis by Treatment
  • Global Anal Fistula Therapeutics Market Research and Analysis by Application
  • Global Anal Fistula Therapeutics Market Research and Analysis by End-User

The Report Covers:

  • Comprehensive research methodology of the global anal fistula therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global anal fistula therapeutics market.
  • Insights about market determinants, which are stimulating the global anal fistula therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Medtronic plc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Karl Storz SE & Co. KG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Cook Group Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Takeda Pharmaceutical Co. Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Signum Surgical Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Anal Fistula Therapeutics Market by Treatment
    • 5.1.1. Surgical
    • 5.1.2. Non-Surgical
  • 5.2. Global Anal Fistula Therapeutics Market by Application
    • 5.2.1. Intersphincteric Fistula
    • 5.2.2. Transsphincteric Fistula
    • 5.2.3. Suprasphincteric Fistula
    • 5.2.4. Others
  • 5.3. Global Anal Fistula Therapeutics Market by End-User
    • 5.3.1. Hospitals
    • 5.3.2. Ambulatory Surgical Centers
    • 5.3.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Medtronic plc
  • 7.2. Cook Group Inc.
  • 7.3. Takeda Pharmaceutical Co. Ltd.
  • 7.4. Karl Storz SE & Co. KG
  • 7.5. Biolitec AG
  • 7.6. Pfizer Inc.
  • 7.7. Becton, Dickinson and Co.
  • 7.8. GEM S.r.l.
  • 7.9. TiGenix NV
  • 7.10. W. L. Gore & Associates, Inc.
  • 7.11. AstraZeneca plc
  • 7.12. Agency for Medical Innovations (A.M.I.) GmbH
  • 7.13. Signum Surgical Ltd.
  • 7.14. Novartis International AG
  • 7.15. Assembly Biosciences, Inc.
  • 7.16. Ovesco Endoscopy AG

LIST OF TABLES

  • 1. GLOBAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 2. GLOBAL SURGICAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL NON-SURGICAL ANAL FISTULA THERAPEUTICS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 5. GLOBAL INTERSPHINCTERIC FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL TRANSSPHINCTERIC FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL SUPRASPHINCTERIC FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL OTHER ANAL FISTULA THERAPEUTICS APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL ANAL FISTULA THERAPEUTICS IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 10. GLOBAL ANAL FISTULA THERAPEUTICS IN AMBULATORY SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL ANAL FISTULA THERAPEUTICS IN OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 16. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 17. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 19. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 20. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 22. ASIA-PACIFIC ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 23. REST OF THE WORLD ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 24. REST OF THE WORLD ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
  • 2. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
  • 3. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY END-USER, 2019 VS 2026 (%)
  • 4. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 5. US ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. CANADA ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. UK ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. FRANCE ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. GERMANY ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ITALY ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. SPAIN ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. ROE ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. INDIA ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. CHINA ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. JAPAN ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 17. REST OF THE WORLD ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)